tradingkey.logo

Penumbra Inc

PEN
View Detailed Chart

252.480USD

-1.730-0.68%
Close 07/31, 16:00ETQuotes delayed by 15 min
9.84BMarket Cap
232.98P/E TTM

Penumbra Inc

252.480

-1.730-0.68%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.68%

5 Days

+8.18%

1 Month

-1.62%

6 Months

-6.14%

Year to Date

+6.32%

1 Year

+45.87%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 19 analysts
BUY
Current Rating
313.375
Target Price
23.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

117
Total
6
Median
8
Average
Company name
Ratings
Analysts
Penumbra Inc
PEN
19
Medtronic PLC
MDT
34
Stryker Corp
SYK
33
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
29
Dexcom Inc
DXCM
28
1
2
3
...
24

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(3)
Neutral(2)
Buy(6)
Indicators
Sell(1)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
3.572
Neutral
RSI(14)
61.075
Neutral
STOCH(KDJ)(9,3,3)
55.017
Buy
ATR(14)
7.120
Low Volatility
CCI(14)
269.150
Overbought
Williams %R
13.892
Overbought
TRIX(12,20)
-0.406
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
234.962
Buy
MA10
232.942
Buy
MA20
238.137
Buy
MA50
251.472
Buy
MA100
265.261
Sell
MA200
256.569
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Ticker SymbolPEN
CompanyPenumbra Inc
CEOMr. Adam Elsesser, J.D.
Websitehttps://www.penumbrainc.com/
KeyAI